Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

January 8, 2018
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference

January 3, 2018
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 11, 2017
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

Read More News

Associated Team Members

Alexis Borisy